<DOC>
	<DOC>NCT03033329</DOC>
	<brief_summary>A Phase 1 study of the safety, tolerability, and pharmacokinetics of a new oxazolidinone antibiotic. In Part 1 cohorts of healthy adults will participate in a single dose escalation study of increasing intravenous doses of MRX-4. In Part 2 cohorts of healthy adults will participate in a multiple dose escalation study of increasing intravenous doses of MRX-4 given twice daily for ten days. Part 3 is a crossover study of oral MRX-4 versus a comparable intravenous dose of MRX-4 to determine bioavailability.</brief_summary>
	<brief_title>Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4</brief_title>
	<detailed_description />
	<criteria>Healthy subjects Underlying hepatic, renal, metabolic, hematologic, cardiovascular, or immunologic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>